MA34827B1 - Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes - Google Patents

Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes

Info

Publication number
MA34827B1
MA34827B1 MA36110A MA36110A MA34827B1 MA 34827 B1 MA34827 B1 MA 34827B1 MA 36110 A MA36110 A MA 36110A MA 36110 A MA36110 A MA 36110A MA 34827 B1 MA34827 B1 MA 34827B1
Authority
MA
Morocco
Prior art keywords
robo1
hybrid protein
treating hepatocarcinoma
hepatocarcinoma
treating
Prior art date
Application number
MA36110A
Other languages
English (en)
Inventor
Frederique Dol-Gleizes
Genevieve Gueguen-Dorbes
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45440542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34827(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR1061163A external-priority patent/FR2969617A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34827B1 publication Critical patent/MA34827B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation d'une protéine recombinante Robo1-Fc pour le traitement du cancer, en particulier d'un hépatocarcinome.
MA36110A 2010-12-23 2011-12-22 Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes MA34827B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1061163A FR2969617A1 (fr) 2010-12-23 2010-12-23 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs.
EP11306336 2011-10-14
PCT/EP2011/073739 WO2012085178A1 (fr) 2010-12-23 2011-12-22 Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes

Publications (1)

Publication Number Publication Date
MA34827B1 true MA34827B1 (fr) 2014-01-02

Family

ID=45440542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36110A MA34827B1 (fr) 2010-12-23 2011-12-22 Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes

Country Status (17)

Country Link
US (1) US20130273049A1 (fr)
EP (1) EP2655408B1 (fr)
JP (1) JP2014507395A (fr)
KR (1) KR20130132880A (fr)
CN (1) CN103703021A (fr)
AR (1) AR084541A1 (fr)
AU (1) AU2011347250B2 (fr)
CA (1) CA2820781A1 (fr)
CL (1) CL2013001861A1 (fr)
CO (1) CO6741197A2 (fr)
EA (1) EA201390955A1 (fr)
MA (1) MA34827B1 (fr)
MX (1) MX2013007421A (fr)
SG (1) SG191060A1 (fr)
UY (1) UY33833A (fr)
WO (1) WO2012085178A1 (fr)
ZA (1) ZA201305266B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
SG11201403746SA (en) 2012-01-05 2014-07-30 Boston Medical Ct Corp Slit-robo signaling for diagnosis and treatment of kidney disease
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104873986A (zh) * 2015-03-23 2015-09-02 广东药学院 一种治疗肝脏纤维化的siRNA及其应用
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
CN110709415A (zh) 2017-06-02 2020-01-17 辉瑞大药厂 重组robo2蛋白、组合物、方法及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
EP1025231B1 (fr) * 1997-10-20 2003-07-16 The Regents of the University of California Robo : une famille de polypeptides et d'acides nucleiques impliques dans le guidage des nerfs
EP2316853A3 (fr) * 2002-03-08 2011-10-05 Shanghai Institutes for Biological Sciences, CAS Detection et modulation de l'angiogenese provoquee par une mediation des slit et des robo, et utilisations correspondantes
DE602005022693D1 (de) * 2004-03-31 2010-09-16 Perseus Proteomics Inc Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörpers
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
TWI570135B (zh) * 2007-04-27 2017-02-11 建南德克公司 高效、穩定且非免疫抑制之抗－ｃｄ４抗體
MX2010002716A (es) * 2007-09-14 2010-07-05 Scil Technology Gmbh Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
FR2958936A1 (fr) * 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用

Also Published As

Publication number Publication date
CO6741197A2 (es) 2013-08-30
UY33833A (es) 2012-07-31
AU2011347250B2 (en) 2015-06-04
KR20130132880A (ko) 2013-12-05
EP2655408A1 (fr) 2013-10-30
MX2013007421A (es) 2014-02-03
CN103703021A (zh) 2014-04-02
CL2013001861A1 (es) 2014-04-04
SG191060A1 (en) 2013-07-31
CA2820781A1 (fr) 2012-06-28
EP2655408B1 (fr) 2016-07-06
EA201390955A1 (ru) 2013-11-29
AU2011347250A1 (en) 2013-05-02
WO2012085178A1 (fr) 2012-06-28
ZA201305266B (en) 2014-09-25
US20130273049A1 (en) 2013-10-17
JP2014507395A (ja) 2014-03-27
AR084541A1 (es) 2013-05-22

Similar Documents

Publication Publication Date Title
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
MA35210B1 (fr) Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer
MA37740A1 (fr) Seringue
EA201171367A1 (ru) Винилиндазолильные соединения
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EA201590997A1 (ru) Соединения и способы их применения
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
MA35180B1 (fr) Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b
EA201490644A1 (ru) Терапевтические пептиды
MY166776A (en) Humanised anti-ctla4 antibodies
LU91805B1 (fr) Compositions inhibitrices de virus pour une utilisation therapeutique in vivo
FR2975600B1 (fr) Agents pour le traitement de tumeurs
FR2960542B1 (fr) Peptide en tant que medicament, en particulier pour le traitement du cancer
MA34878B1 (fr) Utilisation de ligands sigma pour la douleur des cancers des os
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
MA35401B1 (fr) Utilisation de ligands sigma dans une douleur associée au diabète de type 2
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA34952B1 (fr) Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme
MA42166A1 (fr) Seringue
EA201370247A1 (ru) Гипертония и гиперурикемия
MA33842B1 (fr) Utilisation du 2,3-dihydroxypropyl dedecanoate pour le traitement de la seborrhee